Polycythemia vera treatment : Protagonist Therapeutics’ PTG-300 gets FDA ODD

Protagonist Therapeutics has bagged the orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for PTG-300 for polycythemia vera treatment. Polycythemia vera ... Read More